1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to ...
1. Semaglutide 2.4 mg combined with once weekly cagrilintide therapy was not associated with increase in adverse events compared to ...
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients on ...
1. Change in mean bodyweight was -9.6% with semaglutide 2.4 mg vs. -3.4% with placebo. 2. Approximately two-thirds of patients ...
1. Once-weekly treatment of semaglutide was associated with meaningful body weight reduction at 68 weeks compared to placebo in patients ...
1. Nonalcoholic steatohepatitis (NASH) resolution without worsening of fibrosis occurred in a significantly greater percentage of patients who received semaglutide ...
1. Over a median period of almost 16 months, type 2 diabetic (T2DM) patients randomized to oral semaglutide for experienced ...
Over the past 30 years, the transition from print to digital media has contributed to an exponential increase in medical literature. In response, 2 Minute Medicine presents 160+ authoritative, physician-written summaries of the most cited landmark trials in medicine.
